ASX Share rice
Fri 14 Aug 2020 - 09:42:pm (Sydney)

ANP Share Price

ANTISENSE THERAPEUTICS LIMITEDANPPharmaceuticals, Biotechnology & Life Sciences

ANP Company Information

Name:

Antisense Therapeutics Limited

Sector:

Healthcare

Industry:

Drug Manufacturers—Specialty & Generic

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

6-8 Wallace Avenue Toorak Australia 3142

Phone:

61 3 9827 8999

Full Time Employees:

8

CEO, MD & Director:

Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD

CFO & Company Sec.:

Mr. Phillip Allen Hains

Company Overview:

Antisense Therapeutics Limited, a biopharmaceutical drug discovery and development company, engages in the research and development of antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 that has completed Phase IIa for the treatment of multiple sclerosis and asthma. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.

ANP Share Price Information

Shares Issued:

488.78M

Market Capitalisation:

$39.10M

Revenue (TTM):

$641.59K

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.008

Operating Margin (TTM):

$-9.09

Return On Assets (TTM):

$-0.79

Return On Equity (TTM):

$-1.60

Quarterly Revenue Growth (YOY):

0.194

Gross Profit(TTM):

$449.03K

Diluted Earnings Per Share (TTM):

$-0.014

ANP CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$2.40M

Change To Liabilities:

$218.87K

Total Cashflow From Investing Activities:

$2.40M

Net Income:

$-2,944,499

Total Cash From Operating Activities:

$-2,928,436

Depreciation:

$5.38K

Change To Account Receivables:

$-275,306

Sale Purchase Of Stock:

$-67,081

Capital Expenditures:

$0

ANP Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-2,944,499

Net Income:

$-2,944,499

Gross Profit:

$449.03K

Operating Income:

$-3,583,136

Total Revenue:

$586.79K

Total Operating Expenses:

$3.58M

Cost Of Revenue:

$137.76K

ANP Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$888.84K

Total Stockholder Equity:

$2.81M

Other Current Liabilities:

$4.58K

Total Assets:

$3.70M

Common Stock:

$63.94M

Retained Earnings:

$-61,128,738

Other Liabilities:

$9.08K

Cash:

$2.90M

Total Current Liabilities:

$879.76K

Property - Plant & Equipment:

$2.30K

Net Tangible Assets:

$2.81M

Total Current Assets:

$3.70M

Net Receivables:

$834

Short-Term Investments:

$2.30K

Accounts Payable:

$227.13K

Non Currrent Assets (Other):

$2.30K

Short-Term Investments:

$2.30

Non Current Liabilities Total:

$9.08K

ANP Share Price History

ANP News

11 Jun, 2020
Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association (MDA) Virtual 2020 Conference website.
28 May, 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
21 May, 2020
Antisense Therapeutics ("ANP" or the "Company" ASX:ANP | US OTC:ATHJY) is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint confirming the safety and tolerability of ATL1102 for advancement into a potentially pivotal Phase IIb clinical trial.
29 Mar, 2020
Antisense Therapeutics Limited (ASX:ANP) shareholders will doubtless be very grateful to see the share price up 44% in...
27 Feb, 2020
Antisense Therapeutics Limited (ASX:ANP) is pleased to advise of the appointment of Gil Price M.D. as Consultant Medical Director.
29 Jan, 2020
Mark Diamond became the CEO of Antisense Therapeutics Limited (ASX:ANP) in 2001. First, this article will compare CEO...
17 Dec, 2019
Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that the data from all nine participants having completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has affirmed the drug's excellent safety profile and positive drug effects on disease progression endpoints at the low dose tested and in turn the Company's plans to advance ATL1102 into a potentially pivotal Phase IIb clinical trial.
30 Nov, 2019
We can readily understand why investors are attracted to unprofitable companies. By way of example, Antisense...
18 Nov, 2019
MELBOURNE, Australia , Nov. 18, 2019 /PRNewswire/ -- Antisense Therapeutics (ASX: ANP/OTC: ATHJY) is pleased to advise that additional preliminary data analyses from the seven patients who have completed ...
18 Sep, 2019
MELBOURNE, Australia, Sept. 17, 2019 /PRNewswire/ -- Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) therapy, is indicative of a positive drug effect of ATL1102 at the dose tested both at an immunomodulatory (i.e.